DEVOTE Trial: A Plain-English Overview of What It Established

At a glance

| Field | Detail | |---|---| | Trial name | DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec versus Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events) | | N | 7,637 | | Intervention | Insulin degludec (Tresiba) U100, once daily | | Comparator | Insulin glargine U100, once daily | | Duration | Median 2.0 years | | Primary endpoint | First occurrence of MACE: CV death, non-fatal MI, or non-fatal stroke | | Key CV result | HR 0.91 (95% CI 0.78, 1.06); non-inferiority confirmed | | Key hypoglycemia result | 27% lower rate of confirmed nocturnal hypoglycemia (RR 0.73 to 95% CI 0.60, 0.89) |

Why This Trial Existed in the First Place

Before 2008, insulin products were not required to carry cardiovascular outcome data. That changed when the FDA issued guidance demanding that new diabetes therapies demonstrate they do not unacceptably increase CV risk, driven largely by the rosiglitazone controversy. Insulin degludec, a long-acting basal insulin with a half-life of roughly 25 hours and a flat, ultra-stable action profile, received conditional FDA approval in 2015 pending the results of a dedicated cardiovascular outcomes trial. DEVOTE was that trial, published in the New England Journal of Medicine in 2017.

The trial asked two things at once. The regulatory question was whether degludec is cardiovascularly non-inferior to glargine U100. The clinical question, built in as a secondary endpoint, was whether degludec's flatter pharmacokinetic profile would translate into fewer hypoglycemic episodes, particularly the nocturnal variety that patients find most distressing and that observational data had already linked to adverse cardiac events.

Who Was Enrolled and Why That Population Matters

Recruitment targeted adults with type 2 diabetes who were either at high cardiovascular risk or already had established CV disease. The enrollment criteria required one of the following: age 50 or older with at least one CV risk factor, or age 60 or older with at least two CV risk factors, or a prior CV event. In practice, about 85% of participants had established CV disease at baseline. Mean age was roughly 65 years, mean diabetes duration was about 16 years, and mean HbA1c at entry was approximately 8.4%.

This is not a representative type 2 diabetes population. These are patients who were already living with the consequences of long-standing disease. That design choice was deliberate: it accelerated event accrual and let the trial run for a feasible duration, but it limits how confidently clinicians can generalize results to younger, lower-risk patients. When a 52-year-old patient with newly diagnosed T2D asks whether degludec is safer for their heart, DEVOTE does not directly answer that question.

Participants were randomized 1:1 to degludec or glargine, and both insulins were titrated using an identical treat-to-target protocol aiming for a fasting self-monitored blood glucose of 71 to 90 mg/dL. This is methodologically important: the arms were designed to achieve equivalent glycemic control, not just equivalent dosing. Any difference in outcomes could then be attributed to the insulin itself rather than to better or worse glucose management in one group.

The Methodology in Closer Detail

DEVOTE was a double-blind, double-dummy trial, meaning participants injected two pens at each dose time, one active and one placebo, so neither patient nor investigator could tell which product they were receiving. This level of blinding is unusual in insulin trials and meaningfully reduces performance bias.

The primary endpoint, MACE, was adjudicated by an independent committee blinded to treatment assignment. The non-inferiority margin was set at an upper confidence interval bound of 1.30 for the hazard ratio, consistent with the FDA's 2008 guidance and with other large CV outcomes trials in diabetes such as EMPA-REG OUTCOME and LEADER.

The hypoglycemia endpoint was pre-specified as a secondary endpoint, not a post-hoc analysis. Hypoglycemic episodes were classified as confirmed (blood glucose <56 mg/dL or required assistance), severe (requiring third-party assistance), or nocturnal confirmed (occurring between midnight and 5:59 AM). All three categories were tracked prospectively across the entire trial duration, and the analysis used a negative binomial regression to account for repeated events per patient. This matters because a simple "any event" binary analysis would undercount the real burden on patients who experience multiple episodes.

The Results, Laid Out Plainly

Cardiovascular Outcomes

| Endpoint | Degludec | Glargine | HR (95% CI) | p-value | |---|---|---|---|---| | MACE (primary) | 8.5% | 9.3% | 0.91 (0.78, 1.06) | <0.001 for non-inferiority | | CV death | 4.9% | 5.2% | 0.96 (0.79, 1.16) |, | | Non-fatal MI | 3.3% | 3.7% | 0.85 (0.68, 1.07) |, | | Non-fatal stroke | 1.7% | 1.9% | 0.90 (0.65, 1.23) |, |

The trial met its pre-specified non-inferiority threshold. No individual component of MACE reached statistical significance for superiority, which the investigators had specified as a secondary analysis only after confirming non-inferiority. Numerically, every component favored degludec, but none of those differences were significant on their own. Some commentators have suggested the aggregate 9% reduction in MACE deserves more clinical weight than a strict p-value cutoff allows; others note that the confidence interval spans virtually no effect to a meaningful benefit, so caution is appropriate.

Glycemic Control

HbA1c reduction was equivalent between groups (approximately 0.4 percentage points from baseline in both arms), confirming that the treat-to-target design worked as intended. Fasting plasma glucose was also similar. This equivalence is essential to interpreting the hypoglycemia findings: any reduction in hypoglycemia with degludec was not achieved by accepting worse glycemic control.

Hypoglycemia

| Hypoglycemia category | Rate ratio (degludec vs glargine) | 95% CI | p-value | |---|---|---|---| | Confirmed (any time) | 0.83 | 0.74, 0.94 | 0.003 | | Severe (any time) | 0.60 | 0.48, 0.76 | <0.001 | | Confirmed nocturnal | 0.73 | 0.60, 0.89 | 0.002 | | Severe nocturnal | 0.53 | 0.38, 0.73 | <0.001 |

These numbers deserve some unpacking. A 27% lower rate of confirmed nocturnal hypoglycemia and a 40% lower rate of severe hypoglycemia are clinically meaningful differences, not rounding errors. Severe hypoglycemia has well-documented associations with adverse cardiac events, falls, cognitive impairment, and fear-driven under-dosing. The DEVOTE 2 and DEVOTE 3 sub-analyses published alongside the main trial explored the relationship between severe hypoglycemia and subsequent CV events and mortality in more detail, finding that each episode of severe hypoglycemia was independently associated with a higher risk of CV death in both groups. That does not prove causality, but it supports the biological plausibility that reducing hypoglycemia might carry long-term cardiac benefit beyond what this trial was powered to detect.

What the Investigators Said About Limitations

The authors themselves flagged several points worth taking seriously. First, the median follow-up of two years may not be long enough to detect CV differences that accrue over decades of insulin use. Second, the population was heavily weighted toward established CV disease, reducing external validity for primary-prevention patients. Third, although the trial was double-blind, the titration algorithm may have been applied with subtle differences in real-world clinical care that the trial design could not fully replicate. Fourth, glargine U100 was used as the comparator, not glargine U300 (Toujeo), which has a different pharmacokinetic profile and its own hypoglycemia data from the EDITION trials. Degludec has never been directly compared to glargine U300 in a CVOT.

There is also an important commercial context. DEVOTE was funded by Novo Nordisk, the manufacturer of degludec. The authors declare that the funder was involved in study design and data collection, though they note that statistical analysis was independently verified. Readers should apply the same critical lens they would to any industry-sponsored trial, even one that is otherwise methodologically rigorous.

What This Means for Clinical Practice

The FDA removed the post-approval requirement for a CVOT following DEVOTE's results, and the full prescribing information for degludec (Tresiba FDA label) now reflects the cardiovascular safety data. The American Diabetes Association Standards of Care acknowledge the hypoglycemia advantage of degludec and second-generation glargine products relative to NPH and first-generation basals.

In everyday practice, DEVOTE's findings support several specific decisions. For a patient with T2D who has experienced recurrent nocturnal hypoglycemia on glargine U100, degludec is a reasonable switch with evidence-based expectation of fewer episodes at equivalent glycemic control. For a patient with T2D and known CV disease who is starting basal insulin for the first time, degludec and glargine U100 are both cardiovascularly acceptable choices, with the selection hinging on patient preference, cost, formulary access, and hypoglycemia history. For a patient at very low CV risk and no hypoglycemia concerns, cost and access may appropriately drive the choice more than DEVOTE data.

What DEVOTE does not establish: that degludec prevents CV events. The non-inferiority design was not powered to show superiority, and the trial should not be cited as evidence that degludec reduces heart attacks or strokes. That claim would require a different trial design with a different endpoint hierarchy.

---

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Marso SP, McGuire DK, Zinman B, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017;377(8):723-732. https://pubmed.ncbi.nlm.nih.gov/28605603/

2. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME). N Engl J Med. 2015;373(22):2117-2128. https://pubmed.ncbi.nlm.nih.gov/26378978/

3. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med. 2016;375(4):311-322. https://pubmed.ncbi.nlm.nih.gov/27295427/

4. Riddle MC, Bolli GB, Ziemen M, et al. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People with Type 2 Diabetes Using Basal and Mealtime Insulin (EDITION 1). Diabetes Care. 2014;37(10):2755-2762. https://pubmed.ncbi.nlm.nih.gov/24789892/

5. American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2023;46(Suppl 1). https://pubmed.ncbi.nlm.nih.gov/36507635/

6. Tresiba (insulin degludec injection) Full Prescribing Information. Novo Nordisk. FDA label updated 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203314s012lbl.pdf